Oncology Nursing Society

Immunotherapy

Letters

Response to “CAR T-Cell Therapy: Updates in Nursing Management”

Pat Groff

Brittney Baer

CJON 2021, 25(5), 496 DOI: 10.1188/21.CJON.496

I have found Clinical Journal of Oncology Nursing ( CJON ) articles to be enlightening and well written, and I look forward to reading CJON monthly to expand my general cancer care knowledge. I have been a blood and marrow transplantation (BMT) nurse since 1976; our BMT program birthed the chimeric...

No votes yet

Read this Article

Practice Innovations

Immunotherapy Assessment: Using a Survey Instrument to Examine Oncology Nurses’ Confidence Levels With Administration and Management

Barbara J. Offner

Lisa Rinke

CJON 2021, 25(3), 343-346 DOI: 10.1188/21.CJON.343-346

Immuno-oncology is a complex treatment paradigm for many malignancies. As a result, nurses need to increase their knowledge awareness regarding safe, evidence-based care of patients who receive oncologic immunotherapy with their treatment regimen. This pilot study looks at nurse confidence levels...

No votes yet

Read this Article

Evolving Foundations

CAR T-Cell Therapy: Updates in Nursing Management

Brittney Baer

CJON 2021, 25(3), 255-258 DOI: 10.1188/21.CJON.255-258

Chimeric antigen receptor (CAR) T-cell therapy is an evolving treatment used for hematologic malignancies; it requires specialized nursing care and knowledge. This article discusses updates in the nursing management of CAR T-cell therapies and their use in adult patients. A comprehensive review of...

No votes yet

Read this Article

Article

Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer

Marianne Davies

Emily Duffield

CJON 2020, 24(3), 277-283 DOI: 10.1188/20.CJON.277-283

Background: When resection is not an option, platinum-based chemoradiotherapy (CRT) has been the historic standard of care in non-small cell lung cancer (NSCLC). Prognosis remains poor with CRT alone. Durvalumab has shown significant improvement (versus placebo) in progression-free and overall...

No votes yet

Read this Article

Advanced Practice

NCPD Article

Adrenal Insufficiency: Immune Checkpoint Inhibitors and Immune-Related Adverse Event Management

Kiera B. Hobbs

Susan Yackzan

CJON 2020, 24(3), 240-243 DOI: 10.1188/20.CJON.240-243

Adrenal insufficiency (AI) is a potential immune-related adverse event (irAE) of immunotherapy (e.g., checkpoint inhibitor). If not identified and treated promptly, AI can be life-threatening. Unlike other irAEs, AI may be irreversible, requiring long-term glucocorticoid and mineralocorticoid...

Average: 4.4 (5 votes)

Read this Article